stockrow
Friday 6 November 2026
Export ENVB’s income statement to Excel — free account
Enveric Biosciences, Inc.
ENVB Healthcare Biotechnology
- EPS
- +93.5%
- Free cash flow
- −29.3%
Quarter to June 2026, against a year earlier
1.42
0.02
+1.43%
Follow ENVB
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(303.64%) | (420.48%) | (257.95%) | (235.48%) | |
| (245.75%) | (296.67%) | (218.01%) | (193.53%) | ||
ROIC |
0.00% | 0.00% | (3,379.93%) | 0.00% | |
Return on Tangible Assets |
(325.39%) | (290.40%) | (230.02%) | (150.85%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(24.48) | (12.34) | (5.30) | (2.15) | |
Free Cash Flow |
(7.67) | (8.14) | (8.01) | (8.56) | |
| Other line items | |||||
Cash ROIC |
(106.30%) | (91.94%) | (80.31%) | (52.27%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | — | (29,094.67) | |
Operating CF/Net income |
0.68 | 0.67 | 0.69 | 0.71 | |
Depreciation/Fixed assets |
1.24 | 1.26 | 1.31 | 1.88 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(24.48) | (12.34) | (5.30) | (2.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026